Q/C Technologies, Inc. Restricted Cash and Cash Equivalents
Q/C Technologies, Inc. (QCLS) had Restricted Cash and Cash Equivalents of $115.09 thousand as of 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2021-03-01
- 2020-09-30: Restricted Cash and Cash Equivalents $115.09K.
- 2020-06-30: Restricted Cash and Cash Equivalents $115.09K.
- 2020-03-31: Restricted Cash and Cash Equivalents $115.09K.
- 2019-12-31: Restricted Cash and Cash Equivalents $115.09K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2020-09-30 | $115.09K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $115.09K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $115.09K 10-Q · filed 2020-05-15 |
| 2019-12-31 | $115.09K 10-K · filed 2021-03-01 |
| 2019-09-30 | $115.09K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $115.09K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $480.00K 10-Q · filed 2019-05-20 |
| 2018-12-31 | $500.00K 10-K · filed 2020-03-25 |
| 2018-09-30 | $500.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $500.00K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |